Expert Interview
A Third Opinion: Discussing the potential of Semaglutide as a treatment option for heart failure based off the results from the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomized trials.
Ticker(s): NVO, LLY
Institution: Chinatown Cardiology PC
- Clinical Assistant Attending, at Mount Sinai Beth Israel & NYU Langone Medical Centers in General and Interventional Cardiology
- Treats 210 patients with atrial fibrillation at moderate-to-high risk of stroke
- familiar with the publicly available data from the Phase 2 AZALEA-TIMI 71 study comparing Abelacimab to rivaroxaban
- clinical expertise is in performing transradial cardiac catheterization, peripheral endovascular intervention, percutaneous mitral & aortic valvuloplasty, and ASD/PFO closure. He continues to participate in clinical research with a special focus on cardiovascular diseases affecting Asian Americans.
- Dr. Liou is multi-board certified in cardiovascular diseases, echocardiography, nuclear cardiology, and interventional cardiology.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
